Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote "FOR" the merger Transaction expected to be comple ...
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients ...
The Switzerland-based firm's MosaiQ AiPlex Connective Tissue Diseases (CTDplus) assay is used to aid the diagnosis of autoimmune diseases.
AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) microarray. The MosaiQ ...
Anifrolumab can substantially lower the risk for long-term organ damage progression in patients with moderate to severe ...
A risk prediction score that uses machine learning and a patient’s genetic information may identify autoimmune conditions up ...
Indian paediatric rheumatologists discuss early diagnosis and management of rheumatic disorders in children to prevent organ ...
Kris Aquino revealed her "pain and struggle" amid suffering from lupus flare fever for over two weeks now, appealing to the ...
The Lupus Foundation of America describes lupus as a chronic disease that attacks the immune system, the part of the body ...
Pericarditis recurrence in lupus is more likely — and has a dose-dependent relationship — with oral prednisone treatment, ...
Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback